| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
6-Prenylapigenin targets cancer cells through cytotoxic mechanisms. As a prenylated flavonoid, it exhibits anti-tumor activity and antiangiogenic properties. The compound exerts cytotoxicity against leukemia and solid cancer cells. The prenyl group may enhance its membrane interactions and cellular uptake. However, specific molecular targets have not been extensively characterized.
|
|---|---|
| ln Vitro |
In vitro, 6-Prenylapigenin exerts cytotoxicity against cancer cells, including leukemia and solid cancer cells. The compound exhibits anti-tumor activity and antiangiogenic properties. As a prenylated flavonoid, it may induce apoptosis or inhibit cell proliferation through various mechanisms. However, detailed in vitro activity data including IC₅₀ values against specific cancer cell lines have not been extensively published.
|
| ln Vivo |
In vivo activity data for 6-Prenylapigenin are not available in the published literature. The compound has been primarily characterized through in vitro studies showing anti-tumor and antiangiogenic activity. Given its cytotoxicity against cancer cells, potential in vivo studies could include xenograft mouse models. However, such studies have not been reported for this compound.
|
| Enzyme Assay |
In vitro cytotoxicity assays for 6-Prenylapigenin typically involve treating cancer cell lines with varying concentrations of the compound for 48-72 hours, followed by assessment of cell viability using MTT, SRB, or CCK-8 assays. IC₅₀ values are calculated from dose-response curves. Antiangiogenic activity can be evaluated using endothelial cell tube formation assays or migration assays. The compound's structure can be confirmed by NMR and MS. Purity is ≥98%.
|
| Cell Assay |
In vitro cellular assays for 6-Prenylapigenin typically involve evaluation of cytotoxicity in cancer cell lines including leukemia and solid cancer cell lines. Cells are treated with serial dilutions of the compound and cell viability is assessed using MTT or similar assays. Apoptosis induction can be confirmed through flow cytometry using Annexin V/PI staining or by measuring caspase activity. Antiangiogenic effects can be evaluated in endothelial cell cultures.
|
| Animal Protocol |
In vivo animal experiments for 6-Prenylapigenin have not been extensively reported. Based on its anti-tumor and antiangiogenic activities, potential in vivo studies would involve xenograft mouse models using various cancer cell lines. Tumor-bearing mice would be treated with 6-Prenylapigenin via oral or intraperitoneal administration. However, such studies have not been published for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6-Prenylapigenin have not been extensively characterized. The compound has a molecular weight of 338.36 g/mol and a molecular formula of C₂₀H₁₈O₅. As a lipophilic prenylated flavonoid, it is expected to have reasonable membrane permeability and oral bioavailability. The compound appears as a yellow powder. Storage: desiccated at -20°C. Purity ≥98%.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 6-Prenylapigenin has not been extensively documented. As a naturally occurring prenylated flavonoid, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
It has been reported that 6-Prenylapigenin is found in Maclura pomifera, Parartocarpus venenosus, and other organisms with available data.
6-Prenylapigenin (CAS# 68097-13-2, molecular formula C₂₀H₁₈O₅, molecular weight 338.36) is a biologically active flavonoid with anti-tumor activity and antiangiogenic properties. It exerts cytotoxicity against leukemia and solid cancer cells. Also known as 6-Prenyl-4',5,7-trihydroxyflavone. No clinical trials or regulatory approvals have been identified. Purity ≥98%. |
| Molecular Formula |
C20H18O5
|
|---|---|
| Molecular Weight |
338.35
|
| Exact Mass |
338.115
|
| CAS # |
68097-13-2
|
| PubChem CID |
10382485
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
586.1±50.0 °C at 760 mmHg
|
| Flash Point |
212.8±23.6 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.667
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
554
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C\1c3c(O)c(c(O)cc3O/C(=C/1)c2ccc(O)cc2)C\C=C(/C)C
|
| InChi Key |
VJDRSTHNWHVTNQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H18O5/c1-11(2)3-8-14-15(22)9-18-19(20(14)24)16(23)10-17(25-18)12-4-6-13(21)7-5-12/h3-7,9-10,21-22,24H,8H2,1-2H3
|
| Chemical Name |
5,7-dihydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-enyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9555 mL | 14.7776 mL | 29.5552 mL | |
| 5 mM | 0.5911 mL | 2.9555 mL | 5.9110 mL | |
| 10 mM | 0.2956 mL | 1.4778 mL | 2.9555 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
